Annual report [Section 13 and 15(d), not S-K Item 405]

Note 5 - Stock Incentive Plan (Details Textual)

v3.25.1
Note 5 - Stock Incentive Plan (Details Textual) - USD ($)
12 Months Ended
Aug. 05, 2024
Mar. 31, 2022
Apr. 30, 2020
Dec. 31, 2024
Dec. 31, 2023
Aug. 12, 2024
Jun. 30, 2024
Oct. 31, 2017
Apr. 30, 2016
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)       43,523 [1] 101,787        
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value       $ 3,392,518 $ 996,793        
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price (in dollars per share)       $ 19.35          
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Outstanding, Weighted Average Exercise Price (in dollars per share)       21.54          
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expected to Vest, Outstanding, Weighted Average Exercise Price (in dollars per share)       $ 10.99          
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount       $ 1,150,000          
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)       1 year 10 months 13 days          
Share-Based Payment Arrangement, Expense, Tax Benefit       $ 0          
Selling, General and Administrative Expenses [Member]                  
Share-Based Payment Arrangement, Expense       413,496 1,014,046        
Research and Development Expense [Member]                  
Share-Based Payment Arrangement, Expense       $ 727,289 $ 883,803        
Vesting 6/48ths on Six-months and 1/48th After [Member]                  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)       41,523          
Vesting Monthly Over One Year [Member]                  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)       2,000          
Restricted Stock Units (RSUs) [Member]                  
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)       5,997 73,673        
Monopar Therapeutics Inc. 2016 Stock Incentive Plan [Member]                  
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) 7,100,000 1,020,000 620,000     1,420,000 5,100,000 320,000 140,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)   400,000 300,000            
Monopar Therapeutics Inc. 2016 Stock Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member]                  
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)       10 years          
Monopar Therapeutics Inc. 2016 Stock Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Minimum [Member]                  
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)       1 year          
Monopar Therapeutics Inc. 2016 Stock Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Maximum [Member]                  
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)       4 years          
Monopar Therapeutics Inc. 2016 Stock Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member]                  
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)       4 years          
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)       5,997          
Monopar Therapeutics Inc. 2016 Amended Stock Incentive Plan [Member]                  
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) 1,420,000                
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) 400,000                
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)       43,523          
Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share)       $ 1.7          
Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share)       3.71          
Monopar Therapeutics Inc. 2016 Amended Stock Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Minimum [Member]                  
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price (in dollars per share)       1.7          
Monopar Therapeutics Inc. 2016 Amended Stock Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Maximum [Member]                  
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price (in dollars per share)       $ 3.71          
[1] 43,523 options vest as follows: options to purchase 41,523 shares of the Company’s common stock vest 6/48ths on the six-month anniversary of vesting commencement date and 1/48th per month thereafter; and options to purchase 2,000 shares of the Company’s common stock vest monthly over one year. Exercise prices range from $1.70 to $3.71 per share.